First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: A subgroup analysis of data from the FLEX phase 3 study

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F11%3A00002884" target="_blank" >RIV/00216208:11120/11:00002884 - isvavai.cz</a>
Alternative codes found
RIV/00064211:_____/11:#0000107
Result on the web
<a href="http://dx.doi.org/10.1016/S1470-2045(10)70278-3" target="_blank" >http://dx.doi.org/10.1016/S1470-2045(10)70278-3</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S1470-2045(10)70278-3" target="_blank" >10.1016/S1470-2045(10)70278-3</a>

Result language
angličtina
Original language name
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: A subgroup analysis of data from the FLEX phase 3 study
Original language description
The randomised phase 3 First-Line Erbitux in Lung Cancer (FLEX) study showed that the addition of cetuximab to cisplatin and vinorelbine significantly improved overall survival compared with chemotherapy alone in the first-line treatment of advanced non-small-cell lung cancer (NSCLC). The main cetuximab-related side-effect was acne-like rash. Here, we assessed the association of this acne-like rash with clinical benefit
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FC - Pneumology
OECD FORD branch
—

Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)